Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030 - Once Approved, Ubiquitin Enzyme Inhibitors are Poised to Achieve an Accelerated Growth - Research and Markets

DUBLIN, Dec 7, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030" report to their offering.

One of the key objectives of this report was to understand the current activity and the future potential of the market. The study provides a detailed market forecast and opportunity analysis for the period between 2016 and 2030. The research, analysis and insights presented in this report include a detailed description of ubiquitin enzyme inhibitors along with drug classes closely associated with them.

To add robustness to our model, we have provided three scenarios for our market forecast, namely the conservative, base and optimistic scenarios, to account for future uncertainties. The opinions and insights presented in this study were influenced by several discussions conducted with experts in this domain. All actual figures have been sourced and analyzed from publicly available information forums and from primary research. All financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered:

1. Preface
1.1. Chapter Overview
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Chapter Overview
3.2. The Concept of Protein Homeostasis
3.3. Importance of Post Translational Modifications in Cellular Functions
3.4. Discovery of the Ubiquitin/Ubiquitin Proteasome System
3.5. Ubiquitin: Structure and Function
3.6. Fundamentals of the UPS
3.7. Therapeutic Applications of UPS
3.8. Emergence of Ubiquitin Enzyme Inhibitors

4. Ubiquitin Enzyme Inhibitors: Market Overview
4.1. Chapter Overview
4.2. Ubiquitin Enzyme Inhibitors: Development Pipeline
4.3. Ubiquitin Enzyme Inhibitors: Distribution by Phase of Development
4.4. Ubiquitin Enzyme Inhibitors: Distribution by Therapeutic Area
4.5. Ubiquitin Enzyme Inhibitors: Distribution by Target Ubiquitin Enzymes
4.6. Ubiquitin Enzyme Inhibitors: Distribution by Geography
4.7. Ubiquitin Enzyme Inhibitors: Most Active Industry Players
4.8. Ubiquitin Enzyme Inhibitors: Research Tools, Key Technologies and Precursor Compounds

5. Key Insights: Therapeutic Areas and Potential Targets
5.1. Chapter Overview
5.2. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Therapeutic Areas
5.3. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Potential Targets
5.4. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Developer Landscape
5.5. Developers of Ubiquitin Enzyme Inhibitors: Geographical Presence
5.6. Ubiquitin Enzyme Inhibitors and UPS: Recent/Upcoming Conferences

6. E1 and E2 Enzymes as Therapeutic Targets
6.1. Chapter Overview
6.2. E1 Activating Enzymes as Drug Targets
6.3. E2 Conjugating Enzymes as Drug Targets

7. E3 Enzymes as Therapeutic Targets
7.1. Chapter Overview
7.2. E3 Ligases: An Introduction
7.3. E3 Ligases: Mechanism of Action
7.4. E3 Ligases: Important Families
7.5. E3 Ligase Inhibitors: List of Related Targets
7.6. E3 Ligase Inhibitors: Screening Methods
7.7. E3 Ligase Inhibitors: Development Pipeline
7.8. E3 Ligase Inhibitors: Drug Profiles
7.9. E3 Ligase Inhibitors: Challenges and Opportunities

8. DUB Enzymes as Therapeutic Targets
8.1. Chapter Overview
8.2. DUBs: An Introduction
8.3. DUBs: Mechanism of Action
8.4. DUBs: Important Families
8.5. DUB Inhibitors: List of Related Targets
8.6. DUB Inhibitors: Screening Methods
8.7. DUB Inhibitors: Development Pipeline
8.8. DUB Inhibitors: Drug Profiles
8.9. DUB Inhibitors Development: Challenges and Opportunities

9. Associated Drug Classes
9.1. Chapter Overview
9.2. Proteasome Inhibitors
9.3. Immunomodulatory Drugs
9.4. IAP Inhibitors

10. Venture Capital Interest
10.1. Chapter Overview
10.2. Funding Instances: Distribution by Type of Funding
10.3. Funding Instances for Development of Ubiquitin Based Therapeutics
10.4. Rising Venture Capital Interest
10.5. Leading Players: Distribution by Number of Funding Instances
10.6. Most Active Venture Capital Firms/Investors
10.7. Funding Instances: Distribution by Focus Area

11. Recent Collaborations
11.1. Chapter Overview
11.2. Partnership Models/Agreements
11.3. UPS Based Therapeutics: Recent Collaborations
11.4. Recent Collaborations: Distribution by Month/Year
11.5. Recent Collaborations: Distribution by Type of Model
11.6. Recent Collaborations: Distribution by Focus Area
11.7. Recent Collaborations: Most Active Companies

12. Market Forecast and Opportunity Analysis
12.1. Chapter Overview
12.2. Scope and Limitations
12.3. Forecast Methodology
12.4. Overall Ubiquitin Enzyme Inhibitors Market
12.5. Ubiquitin Enzyme Inhibitors Market: Individual Forecasts

13. Conclusion
13.1. Drugs Targeting Protein Modification Pathways Have Emerged as Valuable Therapeutic Options
13.2. Extensive Research is Being Carried Out to Address the Challenges Associated with Drug Discovery
13.3. The Evolving Pipeline Caters to a Wide Spectrum of Disease Indications
13.4. Targeted Therapies are Being Developed by Leveraging Inherent Specificity of Various UPS Components
13.5. Growing Partnerships and VC Support are Indicative of Lucrative Future Potential
13.6. Novel Technology Platforms and Therapeutic Concepts Will Act as Key Enablers to Drive Future Growth
13.7. Once Approved, Ubiquitin Enzyme Inhibitors are Poised to Achieve an Accelerated Growth

14. Interview Transcripts
14.1. Chapter Overview
14.2. Martin Wiles, Vice President Business Development and Licensing, Almac Discovery
 Gerald Gavory, Director of Biology, Almac Discovery
14.3. Katrin Rittinger, Research Group Leader, Francis Crick Institute
14.4. Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry, University Of Delaware

15. Appendix 1: Tabulated Data

16. Appendix 2: List Of Companies And Organizations

• 3SBio
• 5AM Ventures
• ARCH Venture Partners
• Abbiotec
• Abcam
• AcelRx Pharmaceuticals
• Aegera Therapeutics
• Aeneas Ventures
• Agilis Biotherapeutics
• Aileron Therapeutics
• Aju IB Investment
• Alexion Pharmaceuticals
• Almac Discovery
• Amgen
• Angelman Syndrome Foundation
• Apeiron Biologics
• Apple Tree Partners
• Arcus Ventures
• Argenta Discovery
• Argos Soditic
• Arvinas
• Ascenta Therapeutics
• Ascentage Pharma
• Astellas Venture Management
• Astex Pharmaceuticals
• AstraZeneca
• Australasian Leukemia and Lymphoma Group
• Avacta
• BPS Biosciences
• Bavarian Research Foundation
• Bio-Techne
• BioTheryx
• Biogen
• Biogenova
• Biotechnology and Biological Sciences Research Council
• Boehringer Ingelheim
• Boston Biochem
• Boston University Technology Development Fund
• BostonBiochem
• Business Development Bank of Canada
• Business Development Corporation (BDC) Capital
• C4 Therapeutics
• CMEA Ventures
• Calculus Capital
• Canaan Partners
• Cancer Research Technology
• Captor Therapeutics
• Carmot Therapeutics
• Cayman Chemicals
• Celgene Corporation
• Cell Signaling Technology
• CellCentric
• CellXplore
• Cellivery Therapeutics
• Celon Laboratories
• Chinese University of Hong Kong
• Cisbio Bioassays
• Clarus Ventures
• Cleave Biosciences
• Cobro Ventures
• Columbia University
• Comprehensive Cancer Center of Wake Forest University
• Connecticut Innovations
• Cormorant Asset Management
• Curis
• Cyclofluidic
• Daiichi Sankyo
• Dana-Farber Cancer Institute
• Debiopharm
• Desjardins Venture Capital
• Deutsche Bank
• Domain Associates
• Dr. Reddy's
• Draper Esprit
• Draper Fisher Jurvetson
• E3X Bio
• EG Capital Group
• Edmond de Rothschild Investment Partners
• Elan Pharmaceuticals
• Elm Street Ventures
• Encycle Therapeutics
• Endeavour Vision
• Ensemble Therapeutics
• Enterprise Partners
• Enzo Lifesciences
• Erimos Pharmaceutical
• Excel Venture Management
• F-Prime Capital Partners
• Flagship Ventures
• Focus Biomolecules
• Forma Therapeutics
• Foundation Venture Capital Group
• Foundation for Angelman Syndrome Therapeutics (FAST)
• Fox Chase Cancer Center
• Francis Crick Institute
• Genentech (Hoffmann-La Roche)
• GlaxoSmithKline
• GrowthWorks Capital
• Halle University
• Harris & Harris Group
• Harvard Medical School
• Hasso Plattner Ventures
• Hatteras Venture Partners
• HealthCare Ventures
• Horizon Discovery
• Human Genome Sciences
• Hybrigenics
• IP Group
• Imperial Innovations
• Index Ventures
• Innovate UK
• Intrexon
• Invenio Therapeutics
• Investissement Québec
• Janssen Research & Development
• Kamiya Biomedical Company
• Karolinska Institute
• Laboratorio Varifarma
• Latterell Venture Partners
• Life Technologies
• LifeSensors
• Ligand Pharmaceuticals
• Lilly Ventures
• Linköping University
• Lurie Investment Fund
• MVM Life Science Partners
• MaRS Investment Accelerator Fund
• Majuven
• Makoto Life Sciences
• Mayo Clinic
• Medical Research Council
• Memorial Sloan Kettering Cancer Center
• Merck
• Meso Scale Discovery
• MiRx Pharmaceuticals
• Michael J. Fox Foundation
• Millennium Pharmaceuticals
• Miltenyi Biotec
• Mission Therapeutics
• Morningside Venture Investments
• Mount Sinai Hospital's Lunenfeld-Tanenbaum Research Institute
• Multiple Capital
• Natco Pharma
• National Cancer Institute
• National Institutes of Health Small Business Innovation Research
• New Enterprise Associates
• New Leaf Venture Partners
• New York University
• Nextech Invest
• Novartis Pharmaceuticals
• Novitas Capital
• Novus Biologics
• Nurix
• Nxt2b
• Ono Pharmaceutical
• Onyx Pharmaceuticals
• OrbiMed
• Osage University Partners
• Oxford Bioscience Partners
• Parkwalk Advisors
• Peloton Therapeutics
• Penn Pharmaceutical Services
• PerkinElmer
• Perrigo Company
• Perseus
• Pfizer
• Pharmascience
• Pharmion Corporation
• Priaxon
• Progenra
• Promega
• Proteologics
• Proteostasis Therapeutics
• Proteros Biostructures
• Providence Investment Company
• Quaker BioVentures
• Queen's University
• R & D Systems
• RA Capital Management
• Remeditex Ventures
• Rigel Pharmaceuticals
• Roche
• Roswell Park Cancer Institute
• SR One
• SV Life Sciences
• Sanofi
• Sanofi-Genzyme BioVentures
• Santa Cruze Biotech
• Scottish Investment Bank (Investment Arm of Scottish Enterprise)
• Selleckchem
• Sequoia Capital
• Servier
• Sidney Kimmel Comprehensive Cancer Center
• Sigma-Aldrich
• Sofinnova Ventures
• Statsyuk Research Group
• Stemgent
• Supergen
• Taiho Pharmaceutical
• Takeda
• Tensha Therapeutics
• TetraLogic Pharmaceuticals
• The Column Group
• Thermo Fisher Scientific
• Thiel Foundation's Breakout Labs
• Third Rock Ventures
• Tocris
• Tokyo Medical University
• UBP Biotech
• UbiQ Therapeutics
• Ubiquigent
• Universities of Toronto and Sherbrooke
• University of Birmingham
• University of Cambridge Enterprise
• University of Delaware
• University of Dundee
• University of Florida
• University of Glasgow
• University of Liverpool
• University of Michigan
• University of Oxford
• University of Rome Tor Vergata
• University of South Florida (USF)
• University of Texas
• University of Toronto
• Université de Montréal
• VenGrowth Capital Partners
• Vivolux
• Walter and Eliza Hall Institute of Medical Research
• Woodford Patient Capital Trust
• Wren Capital
• Yale University
• Yonsei University College of Medicine
• Yorkville Advisors

For more information about this report visit http://www.researchandmarkets.com/research/qpzw26/ubiquitin

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com